What Is a RAD51C Mutation? Cancer Risk, Inherited vs Somatic Differences, and Current Recommendations

In this article
A Gene Less Known Than BRCA but Just as Worth Knowing: RAD51C and Cancer Risk
RAD51C is one of the genes I now meet more and more often in genetic test reports, besides BRCA1 and BRCA2. This gene helps our cells repair serious DNA damage without errors. In women who carry an inherited (germline) RAD51C mutation, the risk of ovarian (ovary and fallopian tube) cancer by age 80 is about 11%, and the risk of breast cancer about 21%. So RAD51C is not as high-risk as BRCA1 and BRCA2, but it is an important "moderate-risk" gene, especially for ovarian cancer. Acquired (somatic) RAD51C changes that arise later in a tumor are rare; on the other hand, silencing of the gene by methylation in the tumor is common enough in ovarian cancer to affect treatment. In this article I explain what RAD51C is, how inherited and somatic changes differ, current risk estimates for carriers, which variants cause disease, the recommendations in the 2025-2026 guidelines and the effect on treatment. I covered the general logic of hereditary cancer genes in my article on hereditary cancers and targeted therapies (in Turkish).
- What is RAD51C? A gene that works in the same pathway as BRCA1, BRCA2 and PALB2 to repair DNA double-strand breaks without errors (homologous recombination). Cancer risk rises in people who inherit one faulty copy.
- Risks: Ovarian cancer by age 80 about 11% (relative risk ~7.5-fold), breast cancer about 21% (relative risk ~2-fold). Breast cancer risk is especially marked for the triple-negative type. Risks are higher in people with ovarian or breast cancer in the family.
- Somatic change: RAD51C mutations that arise later in the tumor are rare; in ovarian cancer, methylation silencing of the gene can be as common as an inherited mutation. Both can make a tumor sensitive to PARP inhibitors.
- What should be done? In female carriers, removal of the tubes and ovaries is discussed at ages 45-50; annual mammography and breast MRI are considered from age 40. No extra screening is recommended for men. Genetic testing is recommended for relatives.
Why does this topic matter?
As multigene panel tests become widespread, the number of people found to have a change in a non-BRCA gene is rising quickly (best practices in germline variant analysis (in Turkish)). RAD51C is one of them. About 0.5-1% of women diagnosed with ovarian cancer carry an inherited RAD51C mutation. The problem is that knowledge about these genes is not as established as for BRCA; both patients and doctors can struggle to find a clear answer to the question "What does this result mean for me?"
Correct interpretation shapes vital decisions: the timing of preventive ovarian surgery, the intensity of breast screening, testing of relatives, and the choice of treatment if cancer develops. Wrong interpretation leads either to needless anxiety and needless surgery, or to a preventable cancer being missed. This is the distinction I discuss most in my clinic with patients who arrive with a genetic test result: finding a change in a gene is not the same as that change causing disease.
What is a RAD51C mutation?
A RAD51C mutation is a disruptive change in the RAD51C gene, which repairs DNA damage. When inherited, it is present in every cell and raises the risk of ovarian cancer in women about 7.5-fold and the risk of breast cancer about 2-fold. When it arises only in the tumor, it is called a somatic mutation and is not passed on in the family.
Thousands of DNA lesions occur in our cells every day. One of the most dangerous is a break in both strands of the DNA at once. The cell repairs this break without errors by using the intact copy on the sister chromatid as a template; this pathway is called homologous recombination. BRCA1, PALB2 and BRCA2 are the main players in this pathway. RAD51C, together with proteins such as RAD51B, RAD51D and XRCC2, forms "RAD51 paralog complexes" and helps the RAD51 protein, which performs the repair, settle onto the damaged DNA. When RAD51C is impaired, repair falters, errors accumulate and the likelihood of cancer rises (the ATM gene (in Turkish)).
Figure 1 · How does RAD51C work in the cell?
The homologous recombination repair pathway
Inherited or somatic? Why does the difference matter?
RAD51C can appear in four different forms, and each means something different:
- Inherited (germline) single-copy mutation: It comes from the mother or father, is present in every cell of the body and is passed on to children with a 50% probability. This is the situation that raises cancer risk and calls for testing of family members. It is detected with a genetic test on blood or saliva.
- Somatic mutation: It arises only in tumor cells, during the development of the cancer; it is not passed on in the family and does not raise the person's risk of another cancer. Somatic mutations are rare in RAD51C; in large tumor sequencing studies they are seen in fewer than 1% of cancers. When a RAD51C mutation is found in tumor tissue, a blood test must also be done to understand whether it is inherited.
- Promoter methylation (epigenetic silencing): Without any damage to the gene sequence, the gene's "on switch" is chemically turned off. In high-grade serous ovarian cancer, RAD51C methylation is as common as inherited RAD51C mutations and can make the tumor sensitive to PARP inhibitors. However, both copies of the gene must be silenced for this sensitivity; if methylation is lost during treatment, resistance can develop (what is methylation? (in Turkish)).
- Two-copy inherited mutation: Receiving a faulty copy from both mother and father is very rare and causes a Fanconi anemia-like picture in childhood (FANCO): bone marrow failure, developmental abnormalities and cancer predisposition.
Figure 2 · The four forms of RAD51C change
Inherited, somatic, epigenetic and two-copy
Cancer risks in inherited RAD51C carriers
Ovarian (ovary and fallopian tube) cancer
The most reliable risk estimates come from an international analysis of 6,178 families published in 2020 in the Journal of the National Cancer Institute. In this study, the risk of ovarian cancer in women with a RAD51C mutation was about 7.5 times higher than in the general population (relative risk 7.55; 95% CI 5.60-10.19). The risk of ovarian cancer by age 80 is 11% (95% CI 6-21%). In the general population this risk is about 1-1.5%; in BRCA1 carriers around 44% and in BRCA2 carriers around 17% (ovarian cancer guide (in Turkish)).
The risk varies markedly with family history: in a carrier with two first-degree relatives with ovarian cancer, the risk can rise to 32-36%. RAD51C-related ovarian cancers are mostly of the high-grade serous type and arise later than with BRCA1, usually after age 50. For this reason the recommended age for preventive surgery is also later than for BRCA1.
Ovarian cancer risk: up to age 80
Cumulative risk, %; comparison with RAD51C (colored).
In RAD51C carriers the risk varies with family history: in carriers with two first-degree relatives with ovarian cancer, the risk can rise to 32-36%. RAD51C-related ovarian cancer occurs later than with BRCA1, mostly after age 50. The BRCA data are taken from different studies.
Breast cancer
In the same analysis, the risk of breast cancer was about 2-fold (relative risk 1.99; 95% CI 1.39-2.85), with a cumulative risk by age 80 of 21% (95% CI 15-29%). In carriers with two first-degree relatives with breast cancer, the risk can rise to 44-46%. Large case-control studies show that the risk is especially marked for estrogen receptor-negative and triple-negative breast cancer (triple-negative breast cancer (in Turkish), how much breast cancer can be prevented? (in Turkish)). For this reason RAD51C is regarded as a "moderate-risk" gene for breast cancer.
Breast cancer risk: up to age 80
Cumulative risk, %; comparison with RAD51C (colored).
The breast cancer risk associated with RAD51C is moderate (relative risk about 2) and is especially marked in triple-negative breast cancer. In carriers with two first-degree relatives with breast cancer, the risk can rise to 44-46%.
Other cancers and male carriers
There is not enough evidence that the risk of prostate, pancreatic (pancreatic cancer (in Turkish)) or colorectal cancer rises significantly with RAD51C. For example, the Finnish RAD51C founder mutations were not found at all in more than a thousand prostate cancer patients. For this reason no screening beyond what is recommended for the general population is advised for male carriers. However, because male carriers can pass the mutation on to their daughters, they matter for testing within the family. Also, if a man develops prostate cancer, a RAD51C change in the tumor may influence treatment choice (prostate cancer (in Turkish)).
Comparison with other genes
| Gene | Ovarian cancer risk (to age 80) | Breast cancer risk (to age 80) | Preventive ovarian surgery |
|---|---|---|---|
| BRCA1 | ~44% | ~72% | Age 35-40 |
| BRCA2 | ~17% | ~69% | Age 40-45 |
| PALB2 | ~5% | ~53% | May be considered after age 45 |
| RAD51C | ~11% | ~21% | Age 45-50 |
| RAD51D | ~13% | ~20% | Age 45-50 |
| BRIP1 | ~5-15% | No marked increase shown | Age 45-50 |
The values in the table are approximate averages and vary markedly with family history. For details on PALB2 and the BRCA genes, see my articles on BRCA and breast cancer (in Turkish) and olaparib in early-stage disease (in Turkish).
Which RAD51C variants cause disease?
The phrase "RAD51C variant" in a genetic test report says nothing on its own; what matters is the class of the variant. Variants fall into five groups: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign and benign. Clinical decisions are made only on the first two groups.
- Variants that shorten the protein: Nonsense (early stop) and frameshift mutations leave the protein without function, and the great majority are pathogenic. The Finnish founder mutations c.93delG and c.837+1G>A are examples.
- Splice-site variants: Changes that disrupt the reading of the gene; those at canonical splice sites are usually pathogenic.
- Large deletions and duplications: Loss of one or more exons; because they can be missed on standard sequencing, copy number analysis is needed.
- Missense variants: They change a single amino acid; most are harmless but some damage the protein. Most of the VUS in RAD51C belong to this group.
The most important advance in this field was the "saturation genome editing" study published in Cell in 2024. In the laboratory, researchers created 9,188 different RAD51C variants one by one and tested their function inside cells; they showed that 3,094 variants impair gene function. The results agreed with clinical data by more than 99.9%, and data from UK Biobank and more than 8,000 ovarian cancer patients confirmed the link of these variants to cancer. The study also showed that "hypomorphic" variants, which impair function partially rather than completely, are more common than thought and may carry a lower risk. These data help laboratories reclassify uncertain variants. If your result is a VUS, it is worth asking the laboratory every few years whether it has been reclassified (why does the location of the mutation matter? (in Turkish)).
Who should be tested for RAD51C?
RAD51C is not tested on its own but as part of a multigene panel. Panel testing is generally recommended in the following situations: every woman diagnosed with ovarian cancer; triple-negative or young-onset breast cancer; ovarian cancer or several breast cancers in the family; a known mutation in the family. In women diagnosed with ovarian cancer, doing genetic testing right after diagnosis is also important for the treatment plan (ovarian cancer treatment (in Turkish)).
Current recommendations for carriers
The current NCCN recommendations published for 2027 and the ACMG clinical practice resource published in October 2025 suggest the following approach for female carriers:
- Ovary: At ages 45-50, once family planning is complete, preventive removal of the tubes and ovaries should be discussed. If there is early-onset ovarian cancer in the family, an earlier age may be considered. Ovarian screening with ultrasound and CA-125 is not recommended because it has shown no benefit. Birth control pills can reduce the risk of ovarian cancer (preventive surgery (in Turkish)).
- Breast: Annual mammography from age 40 (earlier if there is an earlier diagnosis in the family); annual breast MRI should be considered according to personal risk calculation. Preventive breast surgery is generally not recommended; risk-reducing medicines can be discussed.
- Men: There is no recommendation for extra screening; general population screening is enough.
- Family: Testing for the same variant should be recommended to the mother, father, siblings and adult children. If the partners of carriers who are planning children are also carriers, testing of the partner can be discussed because of the possibility of Fanconi anemia in the child.
Figure 3 · Recommendations for inherited RAD51C carriers
Summary of NCCN and ACMG recommendations
If cancer develops: the effect on treatment
Because loss of RAD51C impairs DNA repair in the tumor, sensitivity to PARP inhibitors and platinum chemotherapy is expected, as in BRCA-mutated tumors (what is olaparib? (in Turkish)). In ovarian cancer, RAD51C-mutated and methylated tumors that responded to PARP inhibitors have been reported; however, it has also been shown that resistance can develop in these tumors through secondary "reversion" mutations that correct the mutation, or through loss of methylation (resistance to PARP inhibitors (in Turkish)). In ovarian cancer, the decision on a PARP inhibitor today is generally made according to BRCA status and the tumor's homologous recombination deficiency (HRD) test; a RAD51C change can affect this test favorably (PARP inhibitors in ovarian cancer (in Turkish), SOLO-1 (in Turkish)).
In studies evaluating PARP inhibitors in metastatic prostate cancer, RAD51C was among the homologous recombination repair genes examined (talazoparib and HRR genes, olaparib and prostate cancer (in Turkish)). However, the benefit in non-BRCA genes is more limited and patient numbers are small. The 2025 ACMG guidance also stresses that the evidence is not yet sufficient to recommend a specific targeted treatment when cancer develops in RAD51C carriers.
The situation in Turkey
In our country multigene panel tests are widely performed and RAD51C is included in most panels. However, genetic counseling before and after the test and interpretation of the results by an experienced team are very important. For suitable patients, clinical trials may also be an option (what is a clinical trial? (in Turkish)). Large-scale data on the frequency of RAD51C carriage in the Turkish population and on common variants are limited; this makes reclassification of VUS results and family segregation analyses even more valuable.
Questions you can ask your doctor
- Is the RAD51C change in my report pathogenic, or a variant of uncertain significance (VUS)?
- Is this change inherited, or was it found only in the tumor?
- Given my family history, what is my personal risk of ovarian and breast cancer?
- At what age should we discuss preventive ovarian surgery?
- Which of my family members should be tested?
- Is a PARP inhibitor an option in my cancer treatment?
- "RAD51C is as risky as BRCA." No. The ovarian cancer risk is about a quarter of that of BRCA1; the breast cancer risk is moderate.
- "If RAD51C is written in the report, I definitely have a risk." No. Only pathogenic and likely pathogenic variants raise risk; clinical decisions are not made on a VUS result.
- "If the tumor has a RAD51C mutation, my family is at risk too." Not always. A somatic mutation is not passed on in the family; whether it is inherited is found out with a blood test.
- "I can catch ovarian cancer early with ultrasound and CA-125." The benefit of screening with these methods has not been shown; the most effective protection is preventive surgery at the right age.
- "It doesn't matter for men." Male carriers do not need extra screening, but they can pass the mutation on to their children.
Frequently Asked Questions
- What is a RAD51C mutation?
- RAD51C is a gene that helps repair DNA double-strand breaks without errors. In women who carry an inherited disruptive change in this gene, the risk of ovarian cancer rises about 7.5-fold and the risk of breast cancer about 2-fold.
- What is the cancer risk in RAD51C carriers?
- The risk of ovarian cancer by age 80 is about 11% and the risk of breast cancer about 21%. Risks are higher in people with ovarian or breast cancer in the family. Breast cancer risk is especially marked for the triple-negative type.
- What should RAD51C carriers do?
- In female carriers, preventive removal of the tubes and ovaries is discussed at ages 45-50, annual mammography is done from age 40 and breast MRI is considered. Ovarian screening is not recommended. Genetic testing is recommended for family members.
- What does a somatic RAD51C mutation mean?
- A somatic mutation is found only in the tumor, is not passed on in the family and is rare. By impairing DNA repair in the tumor, it can increase sensitivity to PARP inhibitors and platinum chemotherapy. A blood test should be done to understand whether it is inherited.
Glossary
- Germline (inherited) mutation
- A gene change present from birth in all cells of the body that can be passed on to children.
- Somatic mutation
- A gene change that arises later only in tumor cells and is not passed on in the family.
- Homologous recombination
- Error-free repair of DNA double-strand breaks using the intact copy as a template.
- Promoter methylation
- Chemical switching off of the gene's "on switch"; the gene is silenced without any change to its sequence.
- Penetrance
- The probability that disease appears in people who carry a mutation.
- VUS
- Variant of uncertain significance; a gene change not yet known to raise cancer risk or not.
- Hypomorphic variant
- A change that impairs gene function partially rather than completely.
- Cascade testing
- Searching for a mutation found in one person among their family members.
- RRSO
- Risk-reducing salpingo-oophorectomy; preventive removal of the tubes and ovaries.
- PARP inhibitor
- A group of targeted drugs aimed at tumor cells with impaired DNA repair; such as olaparib, niraparib and talazoparib.
DROZDOGAN Academy Commentary
RAD51C is one of the best examples of genes that are "not BRCA, but not trivial either." It carries a real and preventable risk for ovarian cancer; for breast cancer it is a moderate-level risk. The key to correct management is correct classification of the variant and personalizing the risk together with family history.
⚡ Why it matters
There is no effective screening method for ovarian cancer; finding carriers and recommending preventive surgery at the right age is therefore the strongest way to prevent this cancer. As panel testing becomes widespread, the number of people who meet a RAD51C result is rising quickly.
✅ Strengths
Risk estimates based on large family data; testing the function of thousands of variants in the laboratory; clear clinical recommendations published in 2025-2026; a biological rationale for the tumor's sensitivity to PARP inhibitors.
⚠️ Limits
The confidence intervals of the risk estimates are wide; the effect of breast MRI and preventive surgery on carriers' life expectancy has not been shown separately; data are insufficient for men and for other cancers; the effectiveness of PARP inhibitors in RAD51C-mutated tumors rests on small patient groups; data specific to the Turkish population are limited.
🩺 In practice
In patients who come with a RAD51C result, I first clarify the class of the variant and whether it is inherited. With female carriers I discuss preventive ovarian surgery from age 45 and intensive breast screening from age 40, and I recommend testing to family members. In my patients with ovarian cancer, I evaluate a RAD51C change together with the HRD test when deciding on a PARP inhibitor.
❓ Open questions
How much risk do hypomorphic variants carry? Should breast MRI be recommended to all carriers, or only to those with a high personal risk? Is removing only the tubes, with later removal of the ovaries, a safe option? Will the place of PARP inhibitors in RAD51C-mutated tumors be clarified by randomized studies?
Conclusion: An inherited RAD51C mutation is an important and manageable risk, especially for ovarian cancer. With correct classification, personalized risk calculation, preventive surgery at the right age and testing of family members, most of this risk can be prevented.
- This article was prepared in November 2026.
- The risk estimates are based on the 2020 international family analysis (Yang et al.); the confidence intervals are wide and personal risk varies with family history. The comparison values for BRCA1 and BRCA2 are taken from different studies.
- The NCCN recommendations are relayed through a patient information source and the ACMG guidance through its summary information; the full texts should be checked.
- Values for the frequency of somatic mutations and methylation may vary between studies.
- The diagrams are simplified. The Academy commentary is mine. This article is not medical advice; evaluate your genetic test results together with your doctor and genetic counselor.
Sources
- Yang X, Song H, Leslie G, et al. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst 2020;112:1242-1250. doi
- Ngeow J, Chiang J, Astiazaran-Symonds E, et al. Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the ACMG. Genet Med 2025. doi
- FORCE. RAD51C: Risk management (NCCN Genetic/Familial High-Risk Assessment v.1.2027). facingourrisk.org
- Olvera-León R, et al. High-resolution functional mapping of RAD51C by saturation genome editing. Cell 2024. pubmed
- Dorling L, et al. Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. N Engl J Med 2021;384:428-439. doi
- Shimelis H, et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. J Natl Cancer Inst 2018. doi
- Nesic K, Kondrashova O, Hurley RM, et al. Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. Cancer Res 2021. qxmd
- Pelttari LM, Nurminen R, Gylfe A, et al. Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients. BMC Cancer 2012;12:552. doi
- Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010;42:410-414. doi
- Kuchenbaecker KB, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017;317:2402-2416. doi
Was this article helpful?
Your feedback helps us improve our content.




